Department

Surgery Sector

Orthopedics, Plastic, Cardiothoracic, Vascular

4 FDA-approved 2 research

HBOT Applications

FDA-Approved Level A

Refractory Osteomyelitis

Standard-of-care adjunctive treatment for chronic osteomyelitis unresponsive to conventional therapy. HBOT enhances leukocyte killing in avascular bone and promotes neovascularization.

Protocol

Pressure

2.0 – 2.4 ATA

Duration

90 min

Sessions

30 – 60

Frequency

Once daily, 5×/week

Evidence basis: UHMS / FDA-Approved

References: 9
FDA-Approved Level A

Crush Injuries & Compartment Syndrome

Approved for acute traumatic ischemias. Reduces post-ischemic edema and preserves threatened tissue in severe crush injuries.

Protocol

Pressure

2.0 – 2.4 ATA

Duration

90 min

Sessions

10 – 20

Frequency

Once daily, 5×/week

Evidence basis: UHMS / FDA-Approved

References: 9
FDA-Approved Level B

Compromised Skin Grafts & Flaps

Salvage therapy for ischemic reconstructive flaps and skin grafts. Reduces hypoxic necrosis through enhanced tissue oxygenation and angiogenesis.

Protocol

Pressure

2.0 – 2.4 ATA

Duration

90 min

Sessions

20 – 30

Frequency

Once daily, 5×/week

Evidence basis: UHMS / FDA-Approved

References: 9
Investigational / Preclinical Level B

Postoperative Recovery (TKA)

Emerging evidence shows HBOT accelerates recovery and reduces muscle damage following total knee arthroplasty and major orthopedic procedures.

Protocol

Pressure

2.0 ATA

Duration

90 min

Sessions

10 – 20

Frequency

Once daily, 5×/week

Evidence basis: Clinical Research

References: 10
FDA-Approved Level B

Thermal Burns

Adjunctive treatment for acute thermal burns. Reduces edema, promotes epithelialization, and decreases infection risk.

Protocol

Pressure

2.0 – 2.4 ATA

Duration

90 min

Sessions

20 – 30

Frequency

Once or twice daily

Evidence basis: UHMS / FDA-Approved

References: 1
Investigational / Preclinical Level C

Therapeutic Angiogenesis (Cardiac)

Investigational use for chronic stable ischemic heart disease and post-MI left ventricular function improvement through VEGF-mediated angiogenesis.

Protocol

Pressure

2.0 – 2.4 ATA

Duration

90 min

Sessions

30 – 40

Frequency

Once daily, 5×/week

Evidence basis: Investigational

References: 12